抗类风湿关节炎新药托法替尼的药理与临床研究进展(2)
第1页 |
参见附件。
[4] United States Food and Drug Administration. Review approved on 11/06/2012 for clinical pharmacology biopharmaceutics review(s) (PDF) [EB/OL]. [2014-01-17]. http: //www.Accessdata.fda.gov/drugsatfda_docs/nda/2012/203214Orig1s000ClinPharmR.Pdf.
[5] 虞忠, 肖坤全. JAK抑制剂临床研究进展[J]. 海峡药学, 2012, 24(1): 18-20.
[6] Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690, 550) [J]. J Immunol, 2011, 186(7): 4234–4243.
[7] Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs[J]. Arthritis Rheum, 2012, 64(3): 617-629.
[8] Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone[J]. Arthritis Rheum, 2012, 64(4): 970-981.
[9] Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis[J]. N Engl J Med, 2012, 367(6): 495–507.
[10] van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis[J]. N Engl J Med, 2012, 367(6): 508–519.
[11] Kontzias A, Kotlyar A, Laurence A, et al. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease[J]. Curr Opin Pharmacol, 2012, 12(4): 464–470.
[12] O’Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase Inhibitors in autoimmune diseases[J]. Ann Rheum Dis, 2013, 72(2): ii111–ii115.
(收稿日期:2014-02-14)
您现在查看是摘要介绍页,详见PDF附件。